Glaukos Rises as Investors Weigh Clinical Progress Ahead of Earnings

Glaukos (GKOS) is up 4.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be driven by a combination of a fresh pipeline milestone and investor positioning ahead of second-quarter results due after the market close on July 29, 2026. This could also reflect continued confidence in the company’s growth story after Glaukos posted strong first-quarter sales growth and lifted its full-year revenue outlook earlier this year.

Details:

Glaukos said on July 27 that it completed patient enrollment in its U.S. pivotal 510(k) study for the PRESERFLO MicroShunt, an important step toward a future FDA submission.

The study enrolled at least 110 patients in the United States and Canada and is aimed at adults with primary open-angle glaucoma whose previous medical and surgical treatment did not adequately control eye pressure.

Glaukos previously said it would release second-quarter 2026 financial results after the close on Wednesday, July 29, 2026, which can attract buying interest as traders position for a report.

In first-quarter 2026 results, the company reported record net sales of $150.6 million, up 41% year over year, and raised full-year 2026 net sales guidance to $620 million to $635 million.

Sources:

Glaukos, Stock Analysis, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GKOS Insider Trading Activity

$GKOS insiders have traded $GKOS stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:

ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 7 sales selling 44,657 shares for an estimated $6,539,359.
JOSEPH E GILLIAM (PRESIDENT & COO) sold 19,573 shares for an estimated $2,809,508
AIMEE S WEISNER has made 0 purchases and 4 sales selling 15,000 shares for an estimated $1,760,761.
GILBERT H KLIMAN has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,378,800.
TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 9 sales selling 5,377 shares for an estimated $647,675.
LEANA WEN sold 1,700 shares for an estimated $243,695

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive GKOS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GKOS Hedge Fund Activity

We have seen 152 institutional investors add shares of $GKOS stock to their portfolio, and 150 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 1,419,970 shares (+5267.7%) to their portfolio in Q1 2026, for an estimated $152,873,970
DRIEHAUS CAPITAL MANAGEMENT LLC added 487,912 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,528,605
UBS GROUP AG removed 487,542 shares (-55.8%) from their portfolio in Q1 2026, for an estimated $52,488,771
JENNISON ASSOCIATES LLC added 487,020 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,432,573
WESTFIELD CAPITAL MANAGEMENT CO LP added 482,219 shares (+inf%) to their portfolio in Q1 2026, for an estimated $51,915,697
MILLENNIUM MANAGEMENT LLC removed 436,003 shares (-27.1%) from their portfolio in Q1 2026, for an estimated $46,940,082
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. added 416,231 shares (+inf%) to their portfolio in Q2 2026, for an estimated $58,172,444

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GKOS Government Contracts

We have seen $201,070 of award payments to $GKOS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TRAVOPROST 75MCG: $169,104
IDOSE TRAVOPROST 75MCG IMPLANT: $21,310
IDOSE TR 75 MGC IMPLANT: $10,655

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$GKOS Analyst Ratings

Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/10/2026

To track analyst ratings and price targets for $GKOS, check out Quiver Quantitative's $GKOS forecast page.

$GKOS Price Targets

Multiple analysts have issued price targets for $GKOS recently. We have seen 7 analysts offer price targets for $GKOS in the last 6 months, with a median target of $162.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $175.0 on 07/08/2026
Yi Chen from HC Wainwright & Co. set a target price of $168.0 on 07/06/2026
Adam Maeder from Piper Sandler set a target price of $165.0 on 07/01/2026
David Saxon from Needham set a target price of $150.0 on 06/17/2026
Ryan Zimmerman from BTIG set a target price of $162.0 on 06/10/2026
Larry Biegelsen from Wells Fargo set a target price of $138.0 on 04/30/2026
Allen Gong from JP Morgan set a target price of $140.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.